Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Tsang, Cecilía J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S002600
Reexamination Certificate
active
07141589
ABSTRACT:
A method of inhibiting formation of vascular channels in tissues and a method of inhibiting proliferation of a cell of a non-vascularized intraepithelial neoplasia, both of which methods comprise administering to the tissues or the cell a compound.
REFERENCES:
patent: 4450150 (1984-05-01), Sidman
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5206343 (1993-04-01), Henke et al.
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5610146 (1997-03-01), Henke et al.
patent: 5665392 (1997-09-01), Kumar et al.
patent: 5789426 (1998-08-01), Hanauske-Abel et al.
patent: 6004986 (1999-12-01), Arthur et al.
patent: 6017522 (2000-01-01), Butterfield et al.
patent: 6046219 (2000-04-01), Hanauske-Abel et al.
patent: 6080766 (2000-06-01), Hanauske-Abel et al.
patent: 6403618 (2002-06-01), Fernandez-Pol
patent: 2775900 (1999-09-01), None
patent: WO 8702580 (1987-05-01), None
patent: WO 92/05190 (1992-04-01), None
patent: WO 99/03823 (1999-01-01), None
patent: WO 99/30562 (1999-06-01), None
patent: WO 02/064620 (2002-08-01), None
patent: WO 02/098853 (2002-12-01), None
patent: WO 2004007676 (2004-01-01), None
A Saaristo, et al. Oncogene (2000) 19, 6122-6129.
PMJ Clement, et al. Int. J. Cancer. (2002) 100, 491-498.
T Linden and RH Wenger. Int. J. Cancer (2003) 106, 458-459.
W. Zundel, et al. Genes & Development. (2001) 14( 4), pp. 391-396.
Abbruzzese et al., “Deoxyhypusine Hydroxylase from Rat Testis,”J. Biol. Chem., 261(7), 3085-3089 (1986).
Andrus et al., “Antiretroviral Effects of Deoxyhypusyl Hydroxylase Inhibitors,”Biochem. Pharmacol., 55(11), 1807-1818 (1998).
Chen et al., “Biochemistry and Function of Hypusine Formation on Eukaryotic Initiation Factor 5A,”Biol. Signals, 6, 105-109 (1997).
Chen et al., “NAD+Stimulated the Spermidine-Dependent Hypusine Formation on the 18 kDa Protein in Cytosolic Lysates Derived from NB-15 Mouse Neuroblastoma Cells,”FEBS Letters, 229(2), 325-328 (1988).
Chvapil et al., “Effect of 1,10-Phenanthroline and DesferrioxamineIn Vivoon Prolyl Hydroxylase and Hydroxylation of Collagen in Various Tissues of Rats,”Biochem. Pharmacol., 23, 2165-2173 (1974).
Csonga et al., “Evaluation of the Metal Ion Requirement of the Human Deoxyhypusine Hydroxylase from HeLa Cells using a Novel Enzyme Assay,”FEBS Lett., 380, 209-214 (1996).
Hanauske-Abel et al., “Inhibition of the G1-S Transition of the Cell Cycle by Inhibitors of Deoxyhypusine Hydroxylation,”Biochim. Biophys. Acta, 1221, 115-124, (1994).
Hoffman et al., “A New Class of Reversible Cell Cycle Inhibitors,”Cytometry, 12, 26-32 (1991).
Ingber et al., “Inhibition of Angiogenesis Through Modulation of Collagen Metabolism,”Lab. Invest., 59(1), 44-51 (1988).
Jastreboff et al., “Role of the Human Papilloma Virus in the Development of Cervical Intraepithelial Neoplasia and Malignancy,”Postgrad. Med. J., 78, 225-228 (2002).
Joura, “Epidemiology, Diagnosis and Treatment of Vulvar Intraepithelial Neoplasia,”Curr. Opin. Obstet. Gynecol., 14, 39-43 (2002).
Kivirikko et al., “Collagen Hydroxylases and the Protein Disulfide Isomerase Subunit of Prolyl 4-Hydroxylases,”Adv. Enzymol. Relat. Areas Mol. Biol., 72, 325-398 (1998).
Küffer et al., “Premalignant Lesions of the Oral Mucosa. A Discussion about the Place of Oral Intraepithelial Neoplasia (OIN),”Oral Oncology, 38, 125-130 (2002).
Lalande et al., “A New Compound which Reversibly Arrests T Lymphocyte Cell Cycle Near the G1/S Boundary,”Exp. Cell. Res., 188, 117-121 (1990).
McCaffrey et al., “Specific Inhibition of elF-5A and Collagen Hydroxylation by a Single Agent,”J. Clin. Invest., 95, 446-455 (1995).
Murphey et al., “Hypusine Formation in Protein by a Two-step Process in Cell Lysates,”J. Biol. Chem., 262, 15033-15036 (1987).
Park et al., “Hypusine Is Essential for Eukaryotic Cell Proliferation,”Biol. Signals, 6, 115-123 (1997).
Park et al., “The Biosynthesis of Protein-bound Hypusine (Ne-(4-Amino-2-hydroxybutyl)Lysine),”J. Biol. Chem., 257(12), 7217-7222 (1982).
Park et al., “Is Hypusine Essential for Eukaryotic Cell Proliferation?,”Trends Biochem. Sci., 18, 475-479 (1993).
Rosenbloom et al., “Inhibition of Proline Hydroxylation does not Inhibit Secretion of Tropoelastine by Chick Aorta Cells,”FEBS Lett., 65(2), 246-250 (1976).
Samuni et al., “Radiation Sensitization of Mammalian Cells by Metal Chelators,”Radiat. Res., 155, 304-310 (2001).
Solomon et al., “The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology,”JAMA, 287(16), 2114-2119 (2002).
Szeimies et al., “Behandlung von therapie-resistenten Verrucae vulgares mit eimen Ciclopirox-haltigen Lack,”Hautarzt, 52, 489-491 (2001).
Wolff et al., “Deoxyhypusine Synthase from Rat Testis: Purification and Characterization,”J. Biol. Chem., 270(15), 8660-8666 (1995).
Ceschin-Roques et al., “Ciclopiroxolamine cream 1%: in vitro and in vivo penetration into the stratum corneum,”Skin Pharmacol., 4(2), 95-99 (1991).
Clement et al., The Antifungal Drug Ciclopirox Inhibits Deoxyhypusine and Proline Hydroxylation, Endothelial Cell Growth and AngiogenesisIn Vivo, Int. J. Cancer, 100, 491-498 (2002).
Cracchiolo et al., “Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva,”Gynecol. Oncol., 94(1), 217-222 (2004).
Fan et al., “Inhibition of N-mycExpression and Induction of Apoptosis by Iron Chelation in Human Neuroblastoma Cells,”Cancer Research, 61(3), 1073-1079 (2001).
Gehse et al., “The effective epidermal inhibition depth of ciclopiroxolamine and naftifin in relation to a galenic preparation,”Mykosen, 30(7), 322-325 (1987).
Georgalas, “Enhanced delivery of an anti-dandruff active in a shampoo vehicle,”J. Cosmet. Sci., 55 Suppl., S207-S214 (2004).
Harada et al., “Angiogenesis and vasodilation in skin warts. Association with HPV infection,”Anticancer Res., 20(6B), 4519-4523 (2000).
Harada et al., “VEGF expression in skin warts. Relevance to angiogenesis and vasodilation,”Arch. Dermatol. Res., 293(5), 233-238 (2001).
Hillebrand et al., “Inhibition of acute ornithine decarboxylase induction can predict tumor prevention by topical photoreceptive agents in the skin of hairless mice exposed to ultraviolet radiation,”J. Soc. Cosmet. Chem., 44(3), 129-138 (1993).
Kicic et al., “Effect of Iron Chelators on Proliferation and Iron Uptake in Hepatoma Cells,”Cancer, 92(12), 3093-3110 (2001).
Le et al., “Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects,”Int J Cancer, 110(3), 468-469 (2004).
Linden et al., The FASEB Journal express article 10. 1096/fj.0586fje. Published online Feb. 19, 2003.
Linden et al., “The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis,”FASEB J., 17(6), 761-763 (2003).
Macpherson et al., “Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay,”Mol. Cancer Ther., 2(9), 845-854 (2003).
Selections from the Physicians Desk Reference, 59th Ed., (2005).
Szeimies et al., “Treatment of recalcitrant common warts with a ciclopirox-containing lacquer,”Hautarzt., 52(6), 489-491 (2001).
Cracchiolo et al., Clinical Protocol No. 0120050348, Grant No. 05-2405-CCR-EO, (1-20), University of New Jersey (2005).
Bevec et al.,Proc. Natl. Acad. Sci. USA, 91, 10829-10833 (1994).
Bonte et al.,Arch Kriminol., 158, 163-174 (1976).
Caraglia et al.,Adv. Exp. Med. Biol., 472, 187-198 (1999).
Donfrancesco et al.,Anti-Cancer Drugs, 4, 317-321 (1993).
Donfrancesco et al.,Anticancer Res., 15, 2347-2350 (1995).
Donfrances
Clement Paul M
Cracchiolo Bernadette M
Hanauske-Abel Hartmut M
Kleinman Hynda K
Park Myung Hee
Kosar Andrew D.
Leydig Voit & Mayer Ltd
The United States of America as represented by the Department of
Tsang Cecila J.
University of Medicine and Dentistry of New Jersey
LandOfFree
Methods of inhibiting formation of vascular channels and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting formation of vascular channels and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting formation of vascular channels and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3666074